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Abstract
Background: The aim of our prospective study was to define the impact of renal dysfunction 
on future cardiovascular events and total mortality in 390 patients suffering from ischemic 
stroke.
Methods: A quantitative measurement of neurologic deficit according to National Institutes 
of Health Stroke Scale (NIHSS) score was performed. Blood parameters were measured. Dia-
betes, hypertension and smoking habits were defined. Estimated glomerular filtration rate was 
calculated.
Results: 153 (39.2%) patients had renal dysfunction. In the follow-up period in 36 (9.2%) 
patients acute coronary syndrome, in 102 (26.2%) recurrent ischemic stroke and in 44 (11.3%) 
peripheral arterial disease were documented. 191 (49%) patient died, 118 (30.3%) of whom 
died of cardiovascular events. Patients who died were older, had higher prevalence of renal 
dysfunction and NIHSS score. The Kaplan-Meier survival analysis showed that total morta-
lity (p < 0.003) and cardiovascular mortality (p < 0.01) were higher in patients with renal 
dysfunction. According to Cox’s regression analysis, renal dysfunction was the predictor of 
cardiovascular events, cardiovascular and total mortality.
Conclusions: Patients with ischemic stroke and renal dysfunction are at higher risk for long 
term cardiovascular and total mortality. The patients with ischemic stroke and renal dysfun-
ction are also at higher risk of new cardiovascular morbidity. Renal dysfunction should be 
added to the other known prognostic factors in patients with ischemic stroke. Our results also 
emphasize the importance of identification and management of renal dysfunction in stroke 
patients. (Cardiol J 2014; 21, 2: 163–169)
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Introduction
Coronary heart disease (CHD) and stroke are 
the main forms of the cardiovascular disease (CVD) 
which is the leading cause of death in Europe, Uni-
ted States and in many other developed countries 
[1]. Chronic kidney disease (CKD) is also a world-
wide public health problem since the incidence 
and the prevalence is rising [2, 3]. Patients with 
renal dysfunction have high prevalence of CHD 
and the prevalence increases with worsening renal 
function, reaching 40% in patients with end stage 
renal disease (ESRD) [4, 5]. Mortality in ESRD 
patients due to CVD is from 10 to 20 times higher 
than in general population [6]. The main reason 
for high prevalence of CHD in patients with renal 
dysfunction is accelerated atherosclerosis, which 
starts already in early stages of renal failure [7]. 
Patients with earlier stages of CKD are not only 
at increased risk of CHD but have also a higher 
CV mortality compared to general population 
[1, 2, 4, 8]. Furthermore, patients with CKD are 
more likely to die of CVD than to start with repla-
cement therapy because of ESRD [9].
It was also shown that in patients with CHD 
the prevalence of renal dysfunction is higher than in 
general population and is estimated to be 18–37% 
[8, 10]. Renal dysfunction was independently as-
sociated with an increased risk of death in patients 
with acute coronary syndrome (ACS) and was also 
strong and independent predictor of increased in-
-hospital and 1-year mortality after percutaneous 
coronary intervention [8, 10].
Patients with CKD and ESRD have also advan-
ced atherosclerosis of cerebral vasculature and are 
at higher risk of ischemic stroke [11]. In the study 
by Nakayama et al. [12] decreased renal function 
was a significant risk factor for first symptomatic 
stroke event in general Japanese population where 
mortality from stroke is 3-fold higher than that in 
the United States. Furthermore, in several studies 
higher prevalence of renal dysfunction in patients 
with ischemic stroke was reported [13, 14]. Renal 
dysfunction was also a predictor of mortality in 
patients with stroke [11, 15]. A meta-analysis of 21 
studies showed that patients with renal dysfunction 
are at greater risk of future ischemic stroke [16]. 
Furthermore, Koren-Morag et al. [17] found that 
patients with established CHD and renal dysfun-
ction are at higher risk of further ischemic stroke. 
Renal dysfunction was established as an impor-
tant independent prognostic marker for ischemic 
stroke risk also after adjustment for traditional 
cerebrovascular risk factors in this study [17]. The 
mechanisms by which renal dysfunction increases 
CV risk are complex [15].
The possible impact of renal dysfunction on 
CV events after stroke is not well known. Tsaga-
lis et al. [13] demonstrated that renal function on 
admission appears to be a significant independent 
prognostic factor for long term mortality and new 
CV morbidity over a 10-year period.
The aim of our study was to define the impact 
of renal dysfunction on future CV events (including 
ACS, recurrent stroke, peripheral arterial disease 
[PAD]), CV death and total mortality in patients 
suffering from ischemic stroke.
Methods
In our prospective study, all 390 Caucasian 
patients with ischemic stroke treated at our De-
partment of Neurology in 1 year period were 
included. Patients were followed from the day of 
admission until their death or maximal 56 months 
(from 1 to 1673 days). Acute ischemic stroke was 
defined according to World Health Organization 
criteria [18]. The stroke was diagnosed in patients 
with appropriate clinical event and was confirmed 
with computed tomography. The patients with 
transitory ischemic attack (TIA) were excluded 
from the study. A study neurologist reviewed all 
cases. On admission, a quantitative measurement 
of neurologic deficit was performed according to 
the National Institutes of Health Stroke Scale 
(NIHSS1) [19]. The same measurement was per-
formed at the day of discharge from the hospital 
(NIHSS2). We collected blood samples from all 
the patients. Serum creatinine, serum cholesterol 
(high density lipoprotein cholesterol [HDL-C] 
and low density lipoprotein cholesterol [LDL-C]), 
triglycerides, high sensitive C-reactive protein 
(hsCRP) and serum albumin were measured by 
routine laboratory methods.
Diabetes mellitus was defined if the patient had 
already been treated for diabetes mellitus (informa-
tion obtained by a questionnaire from patients and/ 
/or their relatives) or fasting glucose value during 
hospital treatment was higher than 7 mmol/L [20].
The arterial hypertension was defined as 
present if the patient had already been  treated for 
hypertension (information obtained by a question-
naire from patients and/or their relatives) or the 
average measure blood pressure was ≥ 140 mm Hg 
systolic or ≥ 90 mm Hg diastolic based on 3 dif-
ferent measurements during hospitalization [21].
With questionnaire we also gathered data 
on smoking habits, patients were divided in two 
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subgroups: smokers (present) and non-smokers. 
According to patient’s weight and height the body 
mass index (BMI) was calculated using BMI for-
mula: body weight (in kilograms)/stature (height, 
in meters) squared.
Estimated glomerular filtration rate (eGFR) 
was calculated according to the abbreviated Modi-
fication of Diet in Renal Disease (aMDRD) formula, 
which is standardized for a 1.73 m2 body surface 
area [7]. Renal dysfunction was defined as eGFR 
under 60 mL/min/1.73 m2.
The CV events were defined as documented 
ACS, documented recurrent ischemic stroke or do-
cumented PAD. Electrocardiography was recorded 
and strips were reviewed by a study cardiologist. 
Atrial fibrillation (AF) was documented.
Informed consent was obtained from each 
patient. The study protocol confirms to the ethical 
guidelines of the 1975 Declaration of Helsinki. The 
study was approved by National Medical Ethic 
Committee of the Republic of Slovenia.
Statistical analysis
SPSS for Windows (version 19.0.1) was used. 
Arithmetic mean values and standard deviation 
were calculated. Survival rates were analyzed 
using Kaplan-Meier survival curves. T-test and 
Mann-Whitney test were performed to compare 
data of patients who survived or died (total and CV 
mortality) and to compare data of patients with or 
without CV events. Cox regression model was used 
to access the influence of renal dysfunction on CV 
events, CV mortality or total mortality. The model 
was also adjusted for several observed cofactors: 
age, gender, smoking, diabetes, hypertension, AF, 
HDL-C and LDL-C, triglycerides, serum albumin, 
hsCRP, NIHSS1 and NIHSS2 score.
Results
Of all included patients 183 (46.9%) were 
women and 207 (53.1%) were men. The mean age 
of the patients included was 70.9 ± 11.64 (ran-
ged: 36–96) years. The mean eGFR was 66.97 ± 
± 21.45 mL/min/1.73 m2. In 153 (39.2%) patients 
renal dysfunction (defined as eGFR under 60 mL/ 
/min/1.73 m2) was found. In majority of patients 
(n = 135; 34.6%) eGFR was between 60 and 30 mL/ 
/min/1.73 m2 and in only 6 (1.5%) patients eGFR 
was under 15 mL/min/1.73 m2. Basic characteristics 
of our patients are presented in Table 1.
Our patients were followed from the day of 
admission to the hospital until maximal 1673 days 
or until their death. In the follow-up period in 
36 (9.2%) patients ACS, in 102 (26.2%) recurrent 
ischemic stroke and in 44 (11.3%) PAD were do-
cumented. In 213 (54.6%) patients no CV events 
were found; 191 (49%) patients died, in 118 (30.3%) 
patients CV death was confirmed.
The Kaplan-Meier survival analysis showed 
that total mortality (p < 0.003) (Fig. 1A) and CV 
mortality (p < 0.01) (Fig. 1B) were higher in pa-
tients with renal dysfunction.
The patients who died were older, had higher 
prevalence of renal dysfunction, more AF, lower 
level of LDL-C and albumin, higher hsCRP, and 
the NIHSS score was higher on admission and 
on discharge. Similar data were found comparing 
patients who died due to CV events or survived. 
No statistically significant difference in presence of 
diabetes, hypertension, smoking, total and HDL-C, 
triglycerides and BMI were found (Table 2).
Comparing the groups of patients with or wit-
hout CV events (using T-test and Mann-Whitney 
test) in observational period patients with CV 
events were older, they had more frequent diabetes 
and AF, NIHSS score was higher on admission and 
on discharge. No statistically significant differences 
in presence of hypertension, smoking habits, total 
cholesterol, LDL-C and HDL-C, triglycerides, 
hsCRP and albumin were found. No difference 
in the presence of renal dysfunction was found 
(Table 3).
According to Cox’s regression analysis renal 
dysfunction was predictor of CV events, CV morta-
Table 1. Basic characteristics of our patients.
Age [years] 70.9 ± 11.64 
Hypertension (proportion) 80.3% (313/390)
Smoking (proportion) 15.6% (61/390)
Diabetes mellitus (proportion) 25.6% (100/390)
Atrial fibrillation (proportion) 20.8% (81/390)
eGFR [mL/min/1.73 m2] 66.97 ± 21.45
Total cholesterol [mmol/L] 5.16 ± 1.30 
LDL-C [mmol/L] 3.18 ± 1.08 
HDL-C [mmol/L] 1.22 ± 0.34 
Triglycerides [mmol/L] 1.92 ± 2.23 
hsCRP [mg/L] 17.8 ± 35.91 
Serum albumin [mmol/L] 40.08 ± 5.05 
BMI [kg/m2] 27.32 ± 4.51 
NIHSS1 [points] 9.6 ± 5.31 
NIHSS2 [points] 8.07 ± 7.44
eGFR — estimated glomerular filtration rate; LDL-C — low density 
lipoprotein cholesterol; HDL-C — high density lipoprotein choleste-
rol; hsCRP — high sensitive C-reactive protein; BMI — body mass 
index; NIHSS1 — National Institutes of Health Stroke Scale — on 
admission; NIHSS2 — National Institutes of Health Stroke Scale  
— on discharge
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lity and total mortality. Renal dysfunction remained 
a strong predictor of CV and total mortality also 
in adjusted Cox regression model (Table 4). The 
probability that patients after ischemic stroke with 
renal dysfunction will have CV event is 1.6 times 
higher than in patients without renal dysfunction. 
The probability for patients with renal dysfunction 
for total mortality is 1.9 times higher and for CV 
mortality 2.4 times higher than in patients without 
renal dysfunction.
Table 2. Comparing patients who died (total and cardiovascular mortality) or survived.  
Survived Died 
Total mortality Cardiovascular mortality 
Age [years] 67.18 ± 11.53 74.93 ± 10.4** 75.37 ± 9.96**
Hypertension (proportion) 79.4% (158/199) 81.2% (155/191) 81.4% (96/118) 
Smoking (proportion) 18.1% (36/199) 13.1% (25/191) 11.0% (13/118)
Diabetes mellitus (proportion) 24.1% (48/199) 27.2% (52/191) 31.4% (37/118)
Atrial fibrillation (proportion) 14.1% (28/199) 27.7% (53/191)* 29.7% (35/118)**
Total cholesterol [mmol/L] 5.43 ± 1.37 4.88 ± 1.16** 4.93 ± 1.19**
LDL-C [mmol/L] 3.32 ± 1.18 3.02 ± 0.96* 3.03 ± 0.94*
HDL-C [mmol/L] 1.25 ± 0.33 1.19 ± 0.36 1.22 ± 0.38
Triglycerides [mmol/L] 2.11 ± 2.57 1.73 ± 1.80 1.65 ± 1.49
hsCRP [mg/L] 10.01 ± 32.18 25.67 ± 37.88** 26.26 ± 34.26**
Serum albumin [mmol/L] 41.86 ± 3.99 38.22 ± 5.36** 38.21 ± 5.51**
BMI [kg/m2] 27.84 ± 4.43 26.77 ± 4.54* 27.00 ± 4.38
NIHSS1 [points] 7.78 ± 3.92 11.49 ± 5.89** 12.05 ± 6.15**
NIHSS2 [points] 4.36 ± 3.17 11.95 ± 8.57** 14.53 ± 9.13**
Renal dysfunction (proportion) 32.2% (64/199) 46.6% (89/191)* 48.3% (57/118)**
*Statistically significant at level p < 0.05; **Statistically significant at level p < 0.001; LDL-C — low density lipoprotein cholesterol;  
HDL-C — high density lipoprotein cholesterol; hsCRP — high sensitive C-reactive protein; BMI — body mass index; NIHSS1 — National  
Institutes of Health Stroke Scale — on admission; NIHSS2 — National Institutes of Health Stroke Scale — on discharge 
Figure 1. A. The Kaplan-Meier survival analysis of total mortality; B. The Kaplan-Meier survival analysis of cardiova-
scular mortality.
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Discussion
In our prospective study, 390 Caucasian adult 
patients with ischemic stroke were enrolled. The 
prevalence of renal dysfunction was 39.2% and 
was higher than in general adult population [2, 6, 22]. 
In only few studies the prevalence of renal dys-
function in patients with ischemic stroke was 
reported. In study by Tsagalis et al. [13] including 
patients with acute stroke (ischemic stroke and 
intra-cerebral hemorrhage), the prevalence of renal 
dysfunction was 28%. Furthermore, the prevalence 
of renal dysfunction in patients with CVD is also 
higher than in general population, reported preva-
lence of renal dysfunction in patients with CHD is 
18–37% [8, 10, 13, 23]. In study by Koren-Morag 
et al. [17], where patients with stable CVD were 
included, the prevalence of ischemic stroke or TIA 
was observed; the prevalence of renal dysfunction 
of included patients was 20%. Further studies 
according to the prevalence of renal dysfunction 
in patients with ischemic stroke are still needed.
Patients with renal dysfunction are at increased 
risk of CVD and in some studies renal dysfunction 
was an independent risk factor for developing CVD 
including stroke [8, 12, 16, 23, 24]. In meta-analysis 
by Lee et al. [16], renal dysfunction defined as 
eGFR < 60 mL/min/1.73 m2 was independently re-
lated to incident ischemic and hemorrhagic stroke. 
Renal dysfunction was an independent predictor of 
the overall composite CV events during the follow-
-up in study by Tsagalis et al. [13]. The composite 
CV events in this study included recurrent stroke, 
new myocardial infarction or unstable angina, new 
Table 3. Comparing data for patients with or without cardiovascular events.
Cardiovascular events
Without With
Age [years] 68.92 ± 12.43 73.44 ± 10.11**
Hypertension (proportion) 80.3% (171/213) 80.2% (142/177)
Smoking (proportion) 17.8% (38/213) 13% (23/177)
Diabetes mellitus (proportion) 20.7% (44/213) 31.6% (56/177)*
Atrial fibrillation (proportion) 16.9% (36/213) 25.4% (45/177)*
Total cholesterol [mmol/L] 5.31 ± 1.36 4.99 ± 1.18* 
LDL-C [mmol/L] 3.28 ± 1.16 3.05 ± 0.98*
HDL-C [mmol/L] 1.21 ± 0.34 1.233 ± 0.35
Triglycerides [mmol/L] 2.14 ± 2.75 1.67 ± 1.34*
hsCRP [mg/L]) 14.95 ± 39.68 20.97 ± 30.54**
Serum albumin [mmol/L] 40.77 ± 4.86 39.24 ± 5.16*
BMI [kg/m2] 27.54 ± 4.66 27.04 ± 4.33
NIHSS1 [points] 8.49 ± 4.49 10.81 ± 5.94**
NIHSS2 [points] 5.40 ± 4.44 11.29 ± 8.93**
Renal dysfunction (proportion) 36.2% (77/213) 42.9% (76/177)
*Statistically significant at level p < 0.05; **Statistically significant at level p < 0.001; LDL-C — low density lipoprotein cholesterol;  
HDL-C — high density lipoprotein cholesterol; hsCRP — high sensitive C-reactive protein; BMI — body mass index; NIHSS1 — National  
Institutes of Health Stroke Scale — on admission; NIHSS2 — National Institutes of Health Stroke Scale — on discharge 
Table 4. Renal dysfunction as a predictor of cardiovascular events, cardiovascular and total mortality.
B p-value HR 95% CI
Cardiovascular events NA 0.321 < 0.036 1.379 1.022–1.861
A 0.468 < 0.007 1.597 1.139–2.238
Cardiovascular mortality NA 0.468 < 0.011 1.596 1.112–2.291
A 0.914 < 0.0001 2.494 1.633–3.807
Total mortality NA 0.422 < 0.004 1.525 1.147–2.027
A 0.637 < 0.0001 1.891 1.371–2.607
A — adjusted model; B — regression coefficient; CI — confidence interval; HR — hazard ratio; NA — non adjusted model
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onset of heart failure, sudden death with or without 
resuscitation, clinical onset of peripheral arterio-
pathy and thoracic or abdominal aortic rupture. 
More than 45% of our patients with ischemic stroke 
suffered at least one CV event in the observational 
period. The probability that patients with renal dys-
function will have CV event was 1.6 times higher 
than in patients without renal dysfunction.
Renal dysfunction predicted total mortality in 
some previous studies; in these studies subgroups of 
patients with ischemic or hemorrhagic stroke were 
not analyzed. Even less is known about CV mortality 
after ischemic stroke. In our study, in observational 
period 191 (49%) patients died, among them 118 
(30.3%) due to CV events. Patients who died (total 
and CV mortality) had higher prevalence of renal 
dysfunction. The Kaplan-Meier survival analysis 
showed that total and CV mortality are higher in 
patients with renal dysfunction after ischemic stro-
ke. Renal dysfunction was also a powerful predictor 
of total and CV mortality in patients with ischemic 
stroke according to Cox’s regression model.
The associations between renal dysfunction 
and CVD including ischemic stroke are numerous. 
Traditional and nontraditional risk factors (age, 
gender, hypertension, diabetes, dyslipidemia, smo-
king, hsCRP, etc.) may play important roles [25]. 
Our patients who died (total and CV mortality) 
were older compared to the survivors. Patients 
who suffered new CV events in the follow-up period 
were also older. Age was associated with worse 
outcome also in the studies of MacWalter et al. [15] 
and Tsagalis et al. [13]. Age was an independent 
predictor of composite CV events in study by Tsa-
galis et al. [13]. This is important because in the 
developed countries population is quickly aging.
Hypertension, diabetes and smoking are 
known important risk factors for stroke. In one 
previous study, patients with documented CHD and 
renal dysfunction had baseline higher proportion 
of hypertension, were less likely to smoke and 
there was no difference in presence of diabetes 
compared to the patients without renal dysfun-
ction [17]. However, the impact of hypertension, 
diabetes and smoking on prognosis or further CV 
events after ischemic stroke is not known. In our 
study, no differences between patients who died 
(total and CV mortality) or survived were found 
in presence of hypertension, diabetes or smoking. 
No difference in hypertension and smoking was 
found also comparing patients with and without 
CV events. The prevalence of diabetes was higher 
in patients with CV events. No difference in BMI 
was found in our patients.
AF is a powerful risk factor for ischemic 
stroke, it is common asymptomatic and therefore 
underestimated [9, 26]. Patients with AF are more 
likely to suffer a recurrent stroke [26]. Also in our 
study the prevalence of AF was higher in patients 
according to total mortality and in patients who 
died due to CV events or had nonfatal CV events. 
AF was a predictor of CV events also in the study 
by Tsagalis et al. [13].
Dyslipidemia is a traditional risk factor for 
CVD [2, 4]. In our study, surprisingly no difference 
in level of LDL-C, HDL-C or level of triglycerides 
between patients after ischemic stroke with or with - 
out CV events was found. Patients who died (total 
mortality and CV mortality) had lower LDL-C. 
Conflicting results on the role of dyslipidemia and 
incident stroke, also in studies including patients 
with renal dysfunction, are reported. In the study 
by Tsagalis et al. [13] no difference in dyslipidemia 
in patients after stroke and renal dysfunction was 
found, but in the study by Koren-Morag et al. [17] 
higher level of HDL-C and lower level of trigly-
cerides in patients with known CHD and renal 
dysfunction after ischemic stroke were found.
In Atherosclerosis Risk in Communities (ARIC) 
study baseline characteristics showed that patients 
with renal dysfunction had higher HDL-C and there 
was no difference in LDL-C [27]. More studies are 
needed to define the impact of dyslipidemia in pa-
tients with ischemic stroke and renal dysfunction.
High serum CRP has been related to the risk 
of cerebrovascular and CV events in patients with 
and without renal dysfunction and was associa-
ted with increased hazard for ischemic stroke in 
patients with known CVD [28]. No large study 
has prospectively assessed the value of CRP for 
prognostic short-term and long-term stratification 
of patients with ischemic stroke. Our patients who 
died (total and CV mortality) had higher hsCRP 
values. Patients who died had also lower serum 
albumin. Together with higher hsCRP values and 
lower LDL-C values possible association between 
malnutrition, inflammation and atherosclerosis 
is suggested, what is common in patients with 
terminal chronic renal failure and is strongly 
associated with accelerated atherosclerosis [29]. 
In our study, no differences in hsCRP and serum 
albumin in patients with or without CV events 
were found.
It is otherwise known that NIHSS has estab-
lished reliability and validity for use in prospec-
tive clinical research, and predictive validity for 
short-term and long-term stroke outcome [30]. 
It is not surprising that our patients who died had 
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higher NIHSS on admission and discharge and that 
higher NIHSS scores in patients with CV events 
were present.
Limitations of the study
The main limitation of our study is that it 
was done only in one medical center. Therefore, 
this fact limits the study’s applicability to general 
population.
Conclusions
Our study demonstrated that the patients with 
ischemic stroke and renal dysfunction are at higher 
risk of long term CV and total mortality. The pa-
tients with ischemic stroke and renal dysfunction 
are also at higher risk of new CV morbidity.
Renal dysfunction should be added to other 
known prognostic factors in patients with ischemic 
stroke. Our results also emphasize the importance 
of identification and management of renal dysfun-
ction in stroke patients.
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